Cargando…
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
BACKGROUND: C3-glomerulopathy (C3G) is a rare pediatric kidney disease characterised by dysregulation of the alternative complement pathway, with glomerular deposition of C3. C3G may often present as a steroid-resistant nephrotic syndrome (SRNS), and there is no established effective therapy: the us...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673980/ https://www.ncbi.nlm.nih.gov/pubmed/37493956 http://dx.doi.org/10.1007/s00467-023-06088-5 |